DexCom, a global leader in continuous glucose monitoring (CGM) systems for people with diabetes has selected Batu Kawan Industrial Park in Penang state as their third manufacturing site and the first manufacturing site outside of the United States. The San Diego-based company plans to utilize the new site to boost the production of Dexcom’s industry-leading CGM systems to meet its growing global demand in the future.
Dexcom Executive Vice President, Chief Financial Officer and Chief Operating Officer Quentin Blackford stated that the growing awareness of Dexcom CGM and the significant growth opportunity for its technology are driving the need for expanded manufacturing. This is in line with Malaysia’s goal to be the manufacturing hub for medical devices in Asia, developing capabilities of producing high value-added and technologically advanced products, such as cardiac pacemakers, stents, orthopedic implantable devices, electro-medical, therapeutic and monitoring devices.
The Malaysian International Trade and Industry (MITI) Minister Datuk Seri Mohamed Azmin Al said Dexcom would benefit from Malaysia’s solid ecosystem backed by strong supporting industries, pragmatic investor-friendly business policies as well as global conformity-assessment bodies that are already present in the country. During 2019, the Malaysian Investment Development Authority approved 31 medical devices manufacturing projects worth MYR 3.98 billion (USD 970 million).
(Sources: The Edge Markets, The Sun Daily)